BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24593764)

  • 1. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
    Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
    Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
    Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
    Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
    Luo Y; Han R; Evanoff DP; Chen X
    Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
    Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
    J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
    Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
    Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer.
    Gan YH; Zhang Y; Khoo HE; Esuvaranathan K
    Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.
    Liu W; O'Donnell MA; Chen X; Han R; Luo Y
    Cancer Immunol Immunother; 2009 Oct; 58(10):1647-55. PubMed ID: 19214503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.
    Luo Y; Yamada H; Evanoff DP; Chen X
    Clin Exp Immunol; 2006 Oct; 146(1):181-8. PubMed ID: 16968412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer.
    Riemensberger J; Böhle A; Brandau S
    Clin Exp Immunol; 2002 Jan; 127(1):20-6. PubMed ID: 11882028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.
    Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M; Ramos KL; Andrade PM
    J Exp Clin Cancer Res; 2008 Nov; 27(1):78. PubMed ID: 19040745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.
    Lattime EC; Gomella LG; McCue PA
    Cancer Res; 1992 Aug; 52(15):4286-90. PubMed ID: 1638541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
    Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
    Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells.
    Thanhäuser A; Böhle A; Schneider B; Reiling N; Mattern T; Ernst M; Flad HD; Ulmer AJ
    Cancer Immunol Immunother; 1995 Feb; 40(2):103-8. PubMed ID: 7882379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy.
    McAveney KM; Gomella LG; Lattime EC
    Cancer Immunol Immunother; 1994 Dec; 39(6):401-6. PubMed ID: 8001028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
    Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
    Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
    Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
    J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.